Eligibility extends to patients with unresectable or metastatic synovial sarcoma who have received prior chemotherapy and meet HLA and MAGE-A4 eligibility criteria LOUISVILLE, Ky., June 22, 2026 /PRNewswire/ -- USWM CT, LLC (US WorldMeds) announced that the U.S. Food and Drug...
Hence then, the article about us worldmeds receives full u s fda approval of tecelra afamitresgene autoleucel with an expanded indication extending the first approved engineered t cell therapy for a solid tumor to children as young as 12 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( US WorldMeds® Receives Full U.S. FDA Approval of TECELRA® (afamitresgene autoleucel) with an Expanded Indication, Extending the First Approved Engineered T-Cell Therapy for a Solid Tumor to Children as Young as 12 )
Also on site :
- Claude and Microsoft 365 Copilot AI Agents Named Champions in Info-Tech Research Group's 2026 Agentic AI Platforms Data Quadrant
- Founders Row Partners with Xtend Barre Founder Andrea Rogers to Launch All Day Pilates, a 24/7 Boutique Reformer Studio Powered by Your Reformer
- Cryptoworth Introduces AI Reconciliation Agent Built for Enterprise Control, Auditability, and Faster Close